InsiderPulse
Dashboard

UTHR

United Therapeutics Corporation

Health CareS&P 500

United Therapeutics Corporation insider trading

United Therapeutics Corporation files with the SEC as a Pharmaceutical Preparations company headquartered in Silver Spring, MD. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent UTHR insider transactions

2 insiders traded UTHR on the open market between Sep 16, 2026 and Sep 17, 2026 — 24 sales worth $13.6M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$13.6M

24 of 24 on a 10b5-1 plan

Net
−$13.6M
Insiders
2

Open-market purchases (code P) and sales (code S) from United Therapeutics Corporation's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 20, 2026. The live dashboard shows new filings the moment they clear.

Every UTHR Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

UTHR insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 14 insiders traded UTHR on the open market: 0 purchases and 2,687 sales worth $1.4B, 2,596 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 1,983 sales ($1.2B), by 12 insiders.

QuarterBoughtSold
Q2 2026—−$491.8M973 sales · 972 on a plan
Q1 2026—−$240.5M467 sales · 462 on a plan
Q4 2025—−$340.7M392 sales · 387 on a plan
Q3 2025—−$98.3M151 sales · 142 on a plan
Q2 2025—−$35.2M61 sales · 58 on a plan
Q1 2025—−$42.3M145 sales · 134 on a plan
Q4 2024—−$81.5M177 sales · 139 on a plan
Q3 2024—−$77.2M321 sales · 302 on a plan
Largest sale
−$7.4M of UTHR by Benkowitz Michael (President And COO) on Dec 29, 2025, under a 10b5-1 plan.

Profile: Martine Rothblatt (Chairperson & CEO) — two years of that insider's own trades, company by company.

Open-market transactions through Jun 30, 2026most recent first

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$1.2M

    Jun 29, 2026

    2,165 sh · $545.30

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$933.2K

    Jun 29, 2026

    1,702 sh · $548.29

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$931.4K

    Jun 29, 2026

    1,705 sh · $546.28

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$867.8K

    Jun 29, 2026

    1,594 sh · $544.40

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$415.3K

    Jun 29, 2026

    759 sh · $547.12

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$317.9K

    Jun 29, 2026

    585 sh · $543.37

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$236.1K

    Jun 29, 2026

    430 sh · $548.96

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$194.8K

    Jun 29, 2026

    360 sh · $541.24

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$64.8K

    Jun 29, 2026

    120 sh · $539.98

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$43.3K

    Jun 29, 2026

    80 sh · $541.86

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$1.2M

    Jun 26, 2026

    2,128 sh · $541.24

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$549.8K

    Jun 26, 2026

    1,012 sh · $543.32

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$549.6K

    Jun 26, 2026

    1,018 sh · $539.89

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$532.9K

    Jun 26, 2026

    983 sh · $542.14

  • Rothblatt Martine A10b5-1

    Chairperson & CEO · Director

    −$478.6K

    Jun 26, 2026

    872 sh · $548.90

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

United Therapeutics Corporation company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Silver Spring, MD
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001082554

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought UTHR

What the stock actually did in the 90 days following each open-market purchase

Don't check UTHR — let it ping you

Get told the moment an insider moves on UTHR

Pro watches United Therapeutics Corporation for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add UTHR to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track UTHR on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read UTHR insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

CORTHRMYSUPNOMCLHQYDOCSOSCRALHCASTHBDXTECHCAH
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are UTHR insiders buying or selling?
Between Sep 16, 2026 and Sep 17, 2026, 2 United Therapeutics Corporation insiders made no open-market purchases and 24 sales worth $13.6M, a net sale of $13.6M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much UTHR stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 14 United Therapeutics Corporation insiders made no open-market purchases and 2,687 sales worth $1.4B. 2596 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 1,983 sales ($1.2B). The largest sale was Benkowitz Michael selling $7.4M on Dec 29, 2025.
What was the largest recent UTHR insider trade?
Mahon Paul A (EVP & General Counsel) sold $1.4M of UTHR stock on Sep 17, 2026 at about $496.58 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy UTHR shares?
No open-market purchase by a United Therapeutics Corporation insider appears in the filings from Sep 16, 2026 to Sep 17, 2026 — every recorded open-market transaction in that period was a sale.
Where does UTHR insider trading data come from?
From the Form 4 filings United Therapeutics Corporation's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.